Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Gene fusions and gene variants associated with cancer
US10072298B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10072298-B2 |
| Application number | US-201514672066-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 27, 2015 |
| Priority date | Apr 17, 2013 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure provides gene fusions, gene variants, and novel associations with disease states, as well as kits, probes, and methods of using the same.
First claim
Opening claim text (preview).
What is claimed: 1. A method of detecting a CEP85L-ROS1 gene fusion in a sample from a subject, the method comprising: generating a reaction mixture comprising nucleic acid from the sample and a pair of primers that specifically hybridize to a target nucleic acid comprising the sequence of SEQ ID NO:17 , wherein the sample comprises the target nucleic acid; amplifying the target nucleic acid using the pair of primers, thereby producing amplicons; sequencing the amplicons; and detecting the presence of a CEP85L-ROS1 gene fusion comprising the sequence of SEQ ID NO:17 in the sequenced amplicons. 2. The method of claim 1 , further comprising diagnosing the subject as having glioblastoma and determining a treatment based on the CEP85L-ROS1 gene fusion detected in the sample. 3. The method of claim 2 , wherein the treatment is crizotinib. 4. The method of claim 1 , wherein the sample is a blood sample. 5. The method of claim 1 , wherein the sample is a tissue sample. 6. The method of claim 5 , wherein the sample is a formalin-fixed, paraffin-embedded sample. 7. The method of claim 1 , wherein the sample comprises tumor tissue. 8. The method of claim 7 , wherein the tumor is a glioblastoma. 9. The method of claim 1 , wherein the sequencing is by next generation sequencing technology.
Assignees
Inventors
Classifications
Physics · mapped topic
Expression markers · CPC title
Physics · mapped topic
- C12Q1/6886Primary
for cancer (immunoassay for cancer G01N33/575) · CPC title
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10072298B2 cover?
- The disclosure provides gene fusions, gene variants, and novel associations with disease states, as well as kits, probes, and methods of using the same.
- Who is the assignee on this patent?
- Life Technologies Corp
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).